Researchers tell us that it’s the technology that drives the innovations and breakthroughs in cancer research. Since 1984 we have provided $184 million to 86 projects within 44 organisations through the generosity of all our supporters working together towards a world without cancer.
The ACRF Medical Research Advisory Committee comprises world-renowned scientists and clinicians who ensure only the most deserving of projects are funded. Ultimately this gives you comfort that your donation will result in real, measurable benefits for those diagnosed with or at risk of cancer.
With input from health economics specialists, we have developed a model to articulate the impact of our supported projects. This will help you understand the value of your support and how it contributes socially, scientifically and economically.
With a minimum contribution of $5,000 you can select which program to pledge your support to, or you can share your contribution across all projects through ‘untied funding’, in a bespoke approach that best aligns with your wishes.
We’ll keep you informed of progress, but you may want to go a little deeper in your understanding of the research by attending special events and tours. Your dedicated relationship manager will tailor your preferences in line with your wishes.
The ACRF ASpIRe Program will leverage new ACRF funded technologies to develop high-resolution, low-cost analyses of the TIME of childhood cancers. This includes a new, innovative platform – the MACSima as well as the Olink system – which will position Australia at the forefront of delivering the first specialised translational TIME profiling program for paediatric cancers.
“ACRF funding is an investment in innovation and new approaches to cancer research. Both in scale and in reach, the ACRF Grant program is a unique and vital part of the cancer research landscape.”
The ACRF Centre for Advanced Cancer Modelling will deliver new knowledge on the mechanisms of resistance to molecular and immune-based therapies in a broad range of cancers. It will also provide insights into protective memory and reveal novel therapeutic targets that can circumvent treatment resistance.
“This ACRF grant is an important catalyst that will expand our research expertise and capabilities by providing access to state-of-the-art equipment and cutting-edge facilities.”
The ACRF Centre for Optimised Cancer Therapy (ACRF COCT), is an ambitious and highly translational initiative that seeks to refine the approach to treating patients with cancer. It will integrate the latest advances in genomics and innovative technologies to understand differences among cells within and between tumours and apply deep learning to large data sets to refine the approach to treating patients with cancer.
ACRF provides funding for new equipment which can dramatically advance the speed and significance of delivering our research findings.”
The ACRF Centre for Precision Medicine will utilise a “theranostic” approach of combined imaging and treatment with novel drugs to enhance therapeutic responses and exploit new technology for tumour treatment.
“The ACRF Centre for Precision Medicine will establish a unique and exciting capability for translation of discoveries into the clinic and provide a key technology for theranostics for multi-centre clinical trials across Australia.”
A Queensland-based, world-first mobile lung cancer research facility focused on early detection research for lung cancer – the leading cause of cancer deaths globally. This pilot program will develop and test a mobile, multi-platform lung cancer detection centre with the aim of reducing health disparities. It will ensure access to rural and remote communities and at-risk populations to ensure equal opportunity for all.
“We have learned from other researchers that trucks can be an alternative way of reaching people who are at risk of lung cancer, to help with screen early detection. This comes from important work in the UK, where trucks have been shown to improve the participation rate, and to allow people to be diagnosed and cured of lung cancer early.”
The new ACRF Molecular Theranostics Laboratory will house world-leading research into the use of theranostics to treat cancer. A form of personalised cancer treatment for the patient, the term ‘theranostics’ refers to a combined therapy and diagnostics approach. An exciting and emerging field, theranostics has the potential to revolutionise cancer treatment, employing tumour markers to deliver a therapeutic isotope (radioactive drug) directly to tumour cells to kill them.
“Researchers at the ACRF Molecular Theranostics Laboratory have devised a theranostic approach that we hope will work against all types of solid tumours. It has an inbuilt self-amplifying mechanism of action, meaning that it should become substantially more effective with each administration.”
To find out more about ACRF Accelerate, download the full prospectus here.
Request more detail
I would love to hear from you. Please fill in some of your details here and I will contact you to discuss your philanthropic wishes and help in any way I can.
*Full Name
*Phone number
*Email Address
Please let us know if there is any information that might help us in tailoring the conversation to your needs.
*Required fields
Δ
If you, like us, believe a world without cancer is possible, please help us in Backing Brilliant scientists and projects to make it happen.